Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.79 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.79 |
| ▸ | CYP8B1 | Q9UNU6 | 3/20 | 0.79 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.79 |
| ▸ | FYN | P06241 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.79 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.79 |
| ▸ | TACR1 | P25103 | 1/20 | 0.79 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.79 |
| ▸ | CCR4 | P51679 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itraconzole SCHEMBL17739437 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL10073778 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL65702 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Saperconazole SCHEMBL65701 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL2615053 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL12887924 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL29371736 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL4149722 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Saperconazole SCHEMBL28021428 | 0.99 | CYP3A4 (0.78) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Saperconazole SCHEMBL28133394 | 0.99 | CYP3A4 (0.78) | CYP3A4ABCG2LMNAMAPTABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0283992-B1 | 4-[4-[4-[4-[[2-(2,4-Difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]triazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-09-16 | — | — | EP | claimed |
| US-4916134-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACUETICA N.V. (BE) | 1990-04-10 | — | — | US | claimed |
| EP-3003038-B1 | 2H-1,2,3-TRIAZOLE DERIVATIVES AS INHIBITORS OF FIBROSIS | SCRIPPS RESEARCH INST (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9981956-B2 | Small molecule inhibitors of fibrosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981956-B2 | Small molecule inhibitors of fibrosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170217943-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-03 | — | — | US | disclosed |
| US-20170217943-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-03 | — | — | US | disclosed |
| US-9663499-B2 | Small molecule inhibitors of fibrosis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663499-B2 | Small molecule inhibitors of fibrosis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160130258-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2016-05-12 | — | — | US | disclosed |
| US-20160130258-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2016-05-12 | — | — | US | disclosed |
| US-6737082-B1 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method | LICONSA LIBERACION CONTROLADA DE SUSTANCIAS ACTIVAS, S.A. (ES) | 2004-05-18 | — | — | US | disclosed |
| US-20040019211-A1 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2003101392-A2 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1350508-A1 | Antifungal formulation and the methods for manufacturing and using the same | Yung Shin Pharm. Ind. Co. Ltd. (TW) | 2003-10-08 | — | — | EP | disclosed |
| EP-1103252-B1 | PHARMACEUTICAL ORAL PREPARATION OF A COMPOUND HAVING AN ANTIFUNGIC ACTIVITY, AND PREPARATION METHOD | LICONSA LIBERACION CONTROLADA (ES) | 2003-03-12 | — | — | EP | disclosed |
| US-20020176894-A1 | Antifungal formulation and the methods for manufacturing and using the same | CARLSBAD TECHNOLOGY, INC. | 2002-11-28 | — | — | US | disclosed |
| EP-1103252-A1 | PHARMACEUTICAL ORAL PREPARATION OF A COMPOUND HAVING AN ANTIFUNGIC ACTIVITY, AND PREPARATION METHOD | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. (ES) | 2001-05-30 | — | — | EP | disclosed |
| US-5998413-A | FUNGICIDE | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-12-07 | — | — | US | disclosed |
| US-4916134-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACUETICA N.V. (BE) | 1990-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130258-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | MMP1, COL2A1, MMP8 | CYP3A4 4660/4885ABCG2 3265/4885LMNA 2026/4885 |
| US-20170217943-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | MMP1, COL2A1, MMP8 | CYP3A4 4660/4885ABCG2 3265/4885LMNA 2026/4885 |
| US-20040019211-A1 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods | CYP51A1, CYP3A5, CYP3A43 | CYP3A4 6/4885ABCG2 80/4885LMNA 3045/4885 |
| US-20020176894-A1 | Antifungal formulation and the methods for manufacturing and using the same | MLEC, SORD, ERG28 | CYP3A4 24/4885ABCG2 261/4885LMNA 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.